P89.06 Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung Cancer
Shingo Matsumoto(National Cancer Center Hospital East), Kōichi Goto(National Cancer Center Hospital East), Jun Sakakibara‐Konishi(Hokkaido University), Kiyotaka Yoh(National Cancer Center Hospital East), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Masahiro Morise(Nagoya University), Yoshitaka Zenke(National Cancer Center Hospital East), Naoki Furuya(St. Marianna University School of Medicine), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Takaya Ikeda(Nagasaki University Hospital), Terufumi Kato(Taipei Veterans General Hospital), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases)
Cited by 7
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k